Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SynKIR 110

Next Previous
Drug Profile

SynKIR 110

Alternative Names: Anti-mesothelin killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapy - Verismo Therapeutics; KIR-CAR-meso - Verismo Therapeutics; SynKIR-meso; SynKIR-meso CAR-T cells; SynKIR™-110

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verismo Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cholangiocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
  • Preclinical Pancreatic cancer; Solid tumours

Most Recent Events

  • 08 Oct 2025 SynKIR 110 is still in phase I trials for Mesothelioma and Ovarian cancer in USA (NCT05568680)
  • 03 Oct 2025 Phase I development for Peritoneal cancer, Fallopian tube cancer, Cholangiocarcinoma, Ovarian cancer and Mesothelioma (Second-line therapy or greater, Late-stage disease) is ongoing in USA (IV)
  • 25 Sep 2025 Verismo Therapeutics plans a phase II trial for solid tumours in an unknown location

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top